ATTO 8-K: Fda approval
Attovia Therapeutics
Filed with the SEC on · accession 0001193125-26-453592
ATTO filed a 8-K (current report) with the SEC on Nov 9, 2026. Attovia Therapeutics announced positive topline 12-week results from its Phase 1b study of ATTO-1310, a next-generation anti-IL-31 therapy, in patients with chronic pruritus and high-itch atopic dermatitis, showing rapid and sustained itch relief and favorable tolerability. The stock moved +4.5% by the first close after the filing.
Summary of the filing
Attovia Therapeutics announced positive topline 12-week results from its Phase 1b study of ATTO-1310, a next-generation anti-IL-31 therapy, in patients with chronic pruritus and high-itch atopic dermatitis, showing rapid and sustained itch relief and favorable tolerability. The company also reported its third quarter 2026 financial results and plans to initiate two Phase 2 trials in the first half of 2027.
Key details
How ATTO stock reacted
Close before
$15.27
Nov 6, 2026
First close after
+4.52%
$15.96
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ATTO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ATTO?
Click hereFrequently asked questions
What did ATTO file with the SEC on Nov 9, 2026?
ATTO filed a 8-K (Fda approval). Attovia Therapeutics announced positive topline 12-week results from its Phase 1b study of ATTO-1310, a next-generation anti-IL-31 therapy, in patients with chronic pruritus and high-itch atopic dermatitis, showing rapid and sustained itch relief and favorable tolerability. The company also reported its third quarter 2026 financial results and plans to initiate two Phase 2 trials in the first half of 2027.
What does a fda approval mean for ATTO stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
How did ATTO stock react to this filing?
ATTO closed at $15.27 before the filing and $15.96 on Nov 9, 2026 (+4.52%).
Other ATTO SEC filings
Get alerts when ATTO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days